Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,600
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$140B
22.46
$5.01
0.35
$3.12
2.81%
Price and volume
Market cap
$140B
Beta
0.35
52-week high
$121.83
52-week low
$77.74
Average daily volume
6.1M
Dividend rate
$3.12
Financial strength
Current ratio
1.315
Quick ratio
0.969
Long term debt to equity
113.017
Total debt to equity
127.34
Dividend payout ratio (TTM)
62.75%
Interest coverage (TTM)
11.04%
Profitability
EBITDA (TTM)
13,801
Gross margin (TTM)
78.53%
Net profit margin (TTM)
21.87%
Operating margin (TTM)
38.22%
Effective tax rate (TTM)
12.36%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
12.62%
Return on equity (TTM)
33.40%
Valuation
Price to earnings (TTM)
22.462
Price to revenue (TTM)
4.861
Price to book
7.11
Price to tangible book (TTM)
-19.4
Price to free cash flow (TTM)
14.976
Free cash flow yield (TTM)
6.68%
Free cash flow per share (TTM)
7.516
Dividend yield (TTM)
2.77%
Forward dividend yield
2.81%
Growth
Revenue change (TTM)
3.81%
Earnings per share change (TTM)
496.80%
3-year revenue growth (CAGR)
1.61%
10-year revenue growth (CAGR)
-0.11%
3-year earnings per share growth (CAGR)
15.28%
10-year earnings per share growth (CAGR)
-6.17%
3-year dividend per share growth (CAGR)
2.70%
10-year dividend per share growth (CAGR)
21.92%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Bulls say / Bears say
The European Commission's approval of lenacapavir for twice-yearly HIV PrEP is expected to drive up to $4 billion in annual sales by 2029, significantly bolstering Gilead's long-term HIV prevention franchise. (Reuters)
Gilead's Q2 2025 HIV product sales grew 7% to $5.1 billion, driven by strong demand and higher prices, enabling the company to raise its full-year revenue and earnings guidance. (Reuters)
The strategic partnership and license agreement with Kymera Therapeutics, valued at up to $750 million, expands Gilead's oncology pipeline with novel CDK2 molecular glue degraders, reinforcing its long-term growth in cancer therapeutics. (Reuters)
Cell therapy revenues fell 7% to $485 million in Q2 2025 as competitive pressure in the CAR-T space intensified, undermining Gilead's cell therapy growth prospects. (Reuters)
Liver disease portfolio sales declined 4% to $795 million in Q2 2025, driven by lower hepatitis C sales amid generic competition and pricing pressures, weighing on Gilead's liver disease franchise. (Reuters)
Despite EU approval of lenacapavir as a twice-yearly HIV PrEP option, its high annual list price of over $28,000 and protracted, country-specific reimbursement negotiations could delay or limit uptake in major European markets. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept15
Gilead Sciences
Dividend·Ex-dividend
Sept29
Gilead Sciences
Dividend·Payment
$0.79Per share
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $140B as of August 29, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 22.46 as of August 29, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of August 29, 2025, the dividend rate is $3.12 and the yield is 2.81%. Gilead Sciences has a payout ratio of 62.75% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for September 29, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.